1
|
Li Z, Mirams GR, Yoshinaga T, Ridder BJ, Han X, Chen JE, Stockbridge NL, Wisialowski TA, Damiano B, Severi S, Morissette P, Kowey PR, Holbrook M, Smith G, Rasmusson RL, Liu M, Song Z, Qu Z, Leishman DJ, Steidl‐Nichols J, Rodriguez B, Bueno‐Orovio A, Zhou X, Passini E, Edwards AG, Morotti S, Ni H, Grandi E, Clancy CE, Vandenberg J, Hill A, Nakamura M, Singer T, Polonchuk L, Greiter‐Wilke A, Wang K, Nave S, Fullerton A, Sobie EA, Paci M, Musuamba Tshinanu F, Strauss DG. General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy. Clin Pharmacol Ther 2020; 107:102-111. [PMID: 31709525 PMCID: PMC6977398 DOI: 10.1002/cpt.1647] [Citation(s) in RCA: 55] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2019] [Accepted: 09/06/2019] [Indexed: 12/27/2022]
Abstract
This white paper presents principles for validating proarrhythmia risk prediction models for regulatory use as discussed at the In Silico Breakout Session of a Cardiac Safety Research Consortium/Health and Environmental Sciences Institute/US Food and Drug Administration-sponsored Think Tank Meeting on May 22, 2018. The meeting was convened to evaluate the progress in the development of a new cardiac safety paradigm, the Comprehensive in Vitro Proarrhythmia Assay (CiPA). The opinions regarding these principles reflect the collective views of those who participated in the discussion of this topic both at and after the breakout session. Although primarily discussed in the context of in silico models, these principles describe the interface between experimental input and model-based interpretation and are intended to be general enough to be applied to other types of nonclinical models for proarrhythmia assessment. This document was developed with the intention of providing a foundation for more consistency and harmonization in developing and validating different models for proarrhythmia risk prediction using the example of the CiPA paradigm.
Collapse
|
2
|
Steidl‐Nichols J, Bhatt S, Hemkens M, Heyen J, Marshall C, Li D, Flynn D, Wisialowski T, Northcott C. Blood pressure and heart rate measures: How well do pre‐clinical models translate? (681.7). FASEB J 2014. [DOI: 10.1096/fasebj.28.1_supplement.681.7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Jill Steidl‐Nichols
- Global Safety Pharmacology (GSP), Drug Safety Research and Development (DSRD) PfizerGrotonCTUnited States
| | - Siddhartha Bhatt
- Global Safety Pharmacology (GSP), Drug Safety Research and Development (DSRD) PfizerGrotonCTUnited States
| | | | | | | | | | - Declan Flynn
- Global Safety Pharmacology (GSP), Drug Safety Research and Development (DSRD) PfizerGrotonCTUnited States
| | - Todd Wisialowski
- Global Safety Pharmacology (GSP), Drug Safety Research and Development (DSRD) PfizerGrotonCTUnited States
| | - Carrie Northcott
- Global Safety Pharmacology (GSP), Drug Safety Research and Development (DSRD) PfizerGrotonCTUnited States
| |
Collapse
|
3
|
Bhatt S, Northcott CA, Ringer L, Wisialowski T, Flynn D, Steidl‐Nichols J. Differential effects of selective versus nonselective alpha adrenergic receptor blockade on cardiovascular (CV) parameters and heart rate variability (HRV) in rats. FASEB J 2013. [DOI: 10.1096/fasebj.27.1_supplement.926.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Siddhartha Bhatt
- Global Safety PharmacologyPfizer Worldwide Research and DevelopmentGrotonCT
| | | | - Laura Ringer
- Global Safety PharmacologyPfizer Worldwide Research and DevelopmentGrotonCT
| | - Todd Wisialowski
- Global Safety PharmacologyPfizer Worldwide Research and DevelopmentGrotonCT
| | - Declan Flynn
- Global Safety PharmacologyPfizer Worldwide Research and DevelopmentGrotonCT
| | | |
Collapse
|